Leerink Partners Downgrades Halozyme Therapeutics (HALO) to Underperform 'On CMS Action'
Tweet Send to a Friend
(Updated - May 13, 2025 8:50 AM EDT)
Leerink Partners analyst David Risinger downgraded Halozyme Therapeutics (NASDAQ: HALO) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst David Risinger downgraded Halozyme Therapeutics (NASDAQ: HALO) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
